13F-HR filed by ARCH Venture Management, LLC
ARCH Venture Management, LLC filed this 13F-HR for the quarter ended 2025-09-30, filed 2025-11-14, with 9 holding rows worth $492,363,653.
- Accession
- 0001012975-25-000787
- Filer
- CIK 1274403
- Filed
- 2025-11-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2025
A holdings report, 9 entries on the cover page, a total value of $492,363,653 stated on the cover page (in dollars after the unit check, H1), rows summing to $492,363,653 with VALUE read as dollars as filed, 13F file number 028-19358. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| RAPPORT THERAPEUTICS INC COM | 75383L102 | Stock | 3,728,738 | $110,743,519 | dollars as filed | |
| BEAM THERAPEUTICS INC | 07373V105 | COM | 4,540,132 | $110,189,004 | dollars as filed | |
| MAZE THERAPEUTICS INC COM | 578784100 | Stock | 4,120,053 | $106,832,974 | dollars as filed | |
| VIR BIOTECHNOLOGY INC | 92764N102 | COM | 12,916,663 | $73,754,146 | dollars as filed | |
| LYELL IMMUNOPHARMA INC COM NEW | 55083R203 | Stock | 2,759,072 | $44,807,329 | dollars as filed | |
| ERASCA INC COM | 29479A108 | Stock | 11,055,554 | $24,101,108 | dollars as filed | |
| GOSSAMER BIO INC COM | 38341P102 | Stock | 8,055,916 | $21,187,059 | dollars as filed | |
| Q32 BIO INC | 746964105 | Common Stock | 320,482 | $634,554 | dollars as filed | |
| CERO THERAPEUTICS HLDGS INC | 71902K402 | COM | 22,389 | $113,960 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001012975-25-000787 | this filing | 2025-11-14 | acceptance time not in the bulk data set |